statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) rose sharply in today's pre-market trading following fourth-quarter results.
read more...

Why Salarius Pharmaceuticals Shares Are Trading Higher By Around 31%; Here Are 20 Stocks Moving Premarket

With U.S. stock futures trading lower this morning on Monday, some of the stocks that may grab investor focus today are as follows:
read more...

Dada Nexus, Salarius Pharmaceuticals And 3 Stocks To Watch Heading Into Monday

Titoli in rialzo
Le azioni di Salarius Pharmaceuticals (NASDAQ:SLRX) sono cresciute del 33,90% a 0,83 dollari durante la sessione after-market di venerd .
Il titolo Masimo (NASDAQ:MASI) ha osservato...

12 titoli sanitari in movimento, after-market del 22/03/2024

Acciones al alza
Salarius Pharmaceuticals (NASDAQ:SLRX) experimentaron un repunte del 35,29% para establecerse en los 0,84 d lares durante la sesi n del after-market del viernes.
Masimo (NASDAQ:MASI...

12 acciones de salud en movimiento en la subasta de cierre del 22/03/2024

Salarius Pharmaceuticals GAAP EPS of -$3.84...

Salarius Pharmaceuticals GAAP EPS of -$3.84

Patient Enrollment Resumed in the Investigator-initiated Phase 1/2 Clinical Trial of Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Company Implemented Significant...

Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Company implementing a series of cost-savings measures designed to extend Salarius' expected cash runway into the first half of 2025 Extended runway supports the generation of additional data from...

Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses

Expands IP portfolio with composition-of-matter protection into 2039 for novel molecular glues Protein degrader portfolio now includes 17 issued patents across six patent families HOUSTON, Jan...

Salarius Pharmaceuticals Issued U.S. Patent for Next-Generation Targeted Protein Degraders

Additional Ewing Sarcoma Patient in Company's Phase 1/2 Sarcoma Trial Achieves Partial Response; Objective Response Rate Among First-Relapse Ewing Patients Treated with Seclidemstat, Topotecan and...

Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals' Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment

Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company, which engages in the development of treatments for cancers with high, unmet medical need. Its pipeline includes SP-3164, a targeted protein degrader and seclidemstat (SP-2577), a targeted protein inhibitor. The company was founded in February 2014 and is headquartered in Houston, TX.

Volume	20,106.00
52-Wk High	$2.31
52-Wk Low	$0.43

SLRX Salarius Pharmaceuticals Inc

About

Feed

News

Earnings

Fundamentals